Magic Mushrooms and Smoking Cessation: New Study Offers Hope for Breaking Addiction
For decades, quitting smoking has remained one of the most difficult health challenges people face. Despite widespread awareness of the risks and a range of available treatments, cigarettes continue to be the leading cause of preventable death across the world.
Now, new research is pointing to an unexpected ally in the fight against nicotine addiction. You guess it, it’s psilocybin, the active compound found in magic mushrooms.
A recent clinical trial from Johns Hopkins University suggests that psilocybin-assisted therapy could dramatically improve smoking cessation outcomes — offering a fresh and promising direction for addiction treatment.
A Breakthrough Moment in Psychedelic Research
Much of the recent attention around psychedelics has focused on their potential for treating depression, anxiety, and post-traumatic stress disorder. This new study expands that conversation, highlighting the role these compounds could play in addressing addiction.
The trial, published in JAMA Network Open, compared nicotine patches (a standard smoking cessation tool) with a single high dose of psilocybin.
After six months, the difference between the two groups was striking.
Participants who received psilocybin had more than six times greater odds of remaining abstinent from cigarettes compared to those using nicotine replacement therapy.
“I was surprised by the sheer magnitude of the effect,” said Matthew Johnson, the study’s lead author and professor of psychiatry at Johns Hopkins.
For a field that has seen slow progress in developing new treatments, results like these are generating genuine excitement.
How the Study Worked
The trial involved 82 current smokers, randomly assigned to one of two groups. One group received nicotine patches, while the other received psilocybin.
All participants took part in cognitive behavioral therapy (CBT) for smoking cessation over 13 weeks, ensuring that psychological support was a central part of the process.
The psilocybin sessions followed a structured format commonly used in psychedelic research. Participants were supported by trained facilitators, designed to help them feel safe and prepared.
During the experience, they lay in a comfortable setting, wore eye shades, and listened to soft music. The experience itself was described as “self-directed,” allowing individuals to navigate their thoughts and emotions in their own way.
Because psilocybin’s effects are so noticeable, participants knew whether they had received the compound. While this can influence results, Johnson noted that maintaining a traditional placebo setup in psychedelic studies presents unique challenges.
The Results: A Clear Difference
At the six-month follow-up, 17 participants in the psilocybin group had successfully quit smoking, compared to just four in the nicotine patch group.
These numbers stand out, especially when compared to existing treatments.
Currently, there are seven medications available for smoking cessation, most of which rely on nicotine replacement methods like gums, lozenges, and patches. Two additional medications — varenicline and bupropion — offer alternative approaches.
Even with these tools, success rates remain limited.
According to Megan Piper, director of the UW Center for Tobacco Research and Intervention, long-term quit rates typically fall between 20% and 30% per attempt when medication is combined with counseling.
“That still means 70% of people are returning to smoking. So how do we help those folks?” she says.
This is where psilocybin’s potential becomes especially significant.
A Completely Different Approach to Addiction
One reason these findings are so encouraging is that psilocybin works in a fundamentally different way from traditional smoking cessation treatments.
Most existing therapies focus on replacing nicotine or reducing withdrawal symptoms. Psilocybin does neither.
Instead, it interacts with the brain’s serotonin system and appears to influence neuroplasticity. This is the brain’s ability to reorganize and form new patterns.
Dr. Brian Barnett, an addiction psychiatrist at the Cleveland Clinic Lerner College of Medicine, described the research as “cutting-edge.”
“Smoking is still a massive public health problem,” he said.
He also noted that psilocybin represents “a very different treatment approach from just trying to replace or sort of mimic the drug that’s being misused.”
Barnett believes the therapy component is just as important as the compound itself.
“It’s not the drug by itself here,” he says. “It’s really harnessing the neuroplastic and learning effects that happen after the [drug] exposure.”
Why Psilocybin May Help People Quit
Researchers are still working to fully understand why psilocybin appears to be so effective in this context. Early clues point toward the way it changes brain activity and perception.
“We already know that when people are on a compound like psilocybin, the brain is communicating with itself in very different ways,” Johnson explained.
Brain imaging data from the study is still being analyzed, but anecdotal reports from participants offer valuable insight.
Many described a shift in perspective. A feeling of stepping outside habitual patterns and seeing their behavior more clearly.
“Rather than falling into the same stories, these same patterns, it seems that things are shaken up and they can step outside of that and try something different,” Johnson said.
This ability to interrupt deeply ingrained habits may be key to addressing addiction, which often operates through repeated behavioral loops.
Building on a Decade of Research
This study didn’t appear out of nowhere. It builds on earlier work by Johnson and his team, including a smaller trial conducted more than ten years ago that also showed promising results.
Together, these findings have been strong enough to attract support from the National Institutes of Health, which is now funding a larger, ongoing study that includes a placebo group.
While replication in larger and more diverse populations is still needed, experts see the current results as a meaningful step forward.
“It’s been 20 years since we’ve had a new medication to help people quit smoking,” Piper said. “We need something novel, and this is definitely a novel approach.”
Psychedelics and Addiction: A Growing Field
Research into psychedelics and addiction is still in its early stages, but interest is expanding.
Studies exploring psilocybin for alcohol dependence have shown promising early results, and clinical trials are ongoing. At the same time, compounds like ibogaine are being investigated for their potential role in treating opioid use disorder.
Despite this growing interest, much of the funding and attention in psychedelic science has focused on mental health conditions such as depression and anxiety.
This new research highlights the importance of expanding that focus.
A Promising Shift for the Future
For those working in public health and addiction treatment, the implications of this study are hard to ignore. Smoking continues to affect millions of people worldwide, and existing treatments leave a large portion of individuals struggling to quit.
The idea that a single psilocybin session, combined with therapeutic support, could significantly improve outcomes represents a major shift in how addiction might be approached in the future. While more research is needed before this treatment becomes widely available, the direction is clear.
Psilocybin may soon be part of an entirely new way of understanding and treating addiction.
And for many people trying to quit smoking, that is genuinely good news.
